AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Public ClinicalTrials.gov record NCT06346392. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator's Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Study identification
- NCT ID
- NCT06346392
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 594 participants
Conditions and interventions
Conditions
Interventions
- AZD0901 Drug
- Ramucirumab+ paclitaxel Drug
- Paclitaxel Drug
- Docetaxel Drug
- Irinotecan Drug
- TAS-102 Drug
- Apatinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 4, 2024 (Actual)
- Primary completion
- May 31, 2026 (Actual)
- Completion
- Oct 14, 2026 (Estimated)
- Last update posted
- Oct 15, 2026
2024 – 2026
United States locations
- U.S. sites
- 26
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Mobile | Alabama | 36604 | — |
| Research Site | Tucson | Arizona | 85719 | — |
| Research Site | Duarte | California | 91010 | — |
| Research Site | Irvine | California | 92618 | — |
| Research Site | Los Angeles | California | 90048 | — |
| Research Site | Los Angeles | California | 90089 | — |
| Research Site | Newport Beach | California | 92663 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Hollywood | Florida | 33021 | — |
| Research Site | Orlando | Florida | 32804 | — |
| Research Site | Marietta | Georgia | 30060 | — |
| Research Site | Boise | Idaho | 83712 | — |
| Research Site | Lexington | Kentucky | 40536 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Ann Arbor | Michigan | 48106 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Kansas City | Missouri | 64111 | — |
| Research Site | Mineola | New York | 11501 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
| Research Site | York | Pennsylvania | 17403 | — |
| Research Site | Charlottesville | Virginia | 22908 | — |
| Research Site | Fredericksburg | Virginia | 22408 | — |
| Research Site | Olympia | Washington | 98502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 132 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06346392, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2026 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06346392 live on ClinicalTrials.gov.